Predicting and Overcoming Taxane Chemoresistance

Taxanes are widely used in the management of breast and ovarian cancer but drug resistance is frequently observed and represents a major limitation of the treatment

Sylvie Rodrigues-Ferreira

2020

Scholarcy highlights

  • Taxanes are widely used in the management of breast and ovarian cancer but drug resistance is frequently observed and represents a major limitation of the treatment
  • Predictive biomarkers for taxane resistance that can be translated into the clinic are urgently needed to determine who will benefit from the therapy and avoid unnecessary treatment and side effects
  • Taxanes are microtubule-targeting drugs used as cytotoxic chemotherapy to treat most solid tumors
  • The development of resistance to taxanes is a major cause of therapeutic failure and overcoming chemoresistance remains an important challenge to improve patient’s outcome
  • Extensive efforts have been made recently to identify predictive biomarkers to select populations of patients who will benefit from taxane-based chemotherapy and avoid inefficient treatment of patients with innate resistance
  • Et al MENA confers resistance to paclitaxel in triple-negative breast cancer.Mol. Cancer Ther

Need more features? Save interactive summary cards to your Scholarcy Library.